Insmed Incorporated (NASDAQ:INSM) Q2 2025 Earnings Call Transcript
Operator: Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today.
Insmed Inc (INSM)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Darwin Global Management Abhishek Trehan | 19,344,621 | $1,924,596,343 | +26% | 80.75% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 7,712,900 | $776,226,256 | +44% | 7.53% |
| 3. | D E Shaw D. E. Shaw | 3,422,619 | $344,452,376 | +366% | 0.24% |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 2,859,452 | $287,775,249 | -18% | 0.48% |
| 5. | Millennium Management Israel Englander | 2,121,717 | $213,529,599 | +213% | 0.1% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $66.35 | 1,130 | $74,975.50 | 3,025 | 2025-05-21 | Filing | |
| $66.87 | 1,895 | $126,718.65 | 1,895 | 2025-05-20 | Filing | |
| $19.29 | 10,000 | $192,900.00 | 10,000 | 2023-05-15 | Filing | |
| $19.29 | 10,000 | $192,900.00 | 298,615 | 2023-05-15 | Filing | |
| $17.70 | 10,000 | $177,000.00 | 15,900 | 2022-11-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $121.58 | 10,000 | $1,215,800.00 | 290,616 | 2025-08-12 | Filing | |
| $110.91 | 1,938 | $214,943.58 | 233,924 | 2025-08-04 | Filing | |
| $109.68 | 3,199 | $350,866.32 | 235,862 | 2025-08-04 | Filing | |
| $108.80 | 1,693 | $184,198.40 | 239,061 | 2025-08-04 | Filing | |
| $109.50 | 8,715 | $954,292.50 | 83,111 | 2025-08-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,644,492 | $1,775,741,675 | 0.03% | |
| 2. | 15,636,399 | $1,573,647,331 | 0.1% | |
| 3. | 11,142,432 | $1,121,374,365 | 0.02% | |
| 4. | 7,478,859 | $752,672,370 | 0.13% | |
| 5. | 5,093,261 | $512,585,854 | 0.03% |
News See All
Insmed’s Pipeline Growth With Brensocatib Approval And Phase 3 Trials
New Jersey-based company, Insmed Incorporated (NASDAQ:INSM), is a global biopharmaceutical company developing life‑altering therapies for serious and rare diseases.
Strong Drug Development Momentum Lifted Insmed Incorporated (INSM) in Q2
Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
10 Stocks with Huge Catalysts on the Horizon
When the president of the US leaves a meeting with the Federal Reserve sounding confident that interest rates will fall, investors cannot help but take notice.
Wells Fargo Lifts PT on Insmed Incorporated (INSM) to $130 From $119, Keeps a Buy Rating
Insmed Incorporated (NASDAQ:INSM) is one of the best strong buy healthcare stocks to buy now.
10 Best Strong Buy Healthcare Stocks to Buy Now
On July 21, Jared Holz, Mizuho health care sector strategist, appeared on CNBC's 'The Exchange' to talk about whether any opportunity plays exist within the healthcare sector, and what pains the sector...
Jim Cramer Calls Insmed "Very Speculative"
Insmed Incorporated (NASDAQ:INSM) is one of the stocks on Jim Cramer’s radar. A caller noted that Cramer has not been quick to recommend biotech companies in the past and inquired about Insmed.
20 Stocks on Jim Cramer’s Radar
On Wednesday, Mad Money host Jim Cramer pointed out that investors are getting sidetracked by the relentless stream of political headlines and are missing out on significant developments in the corporate...
What Makes Insmed Incorporated (INSM) an Investment Bet?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” first quarter 2025 investor letter.
Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110
Insmed Inc. (NASDAQ:INSM) is one of the 10 best growth stocks to buy according to billionaires.
Billionaire Hedge Funds
